caa a22 4500 46579016X CHVBK 20180323112021.0 cr unu---uuuuu 170327e19900501xx s 000 0 eng 10.1007/BF00177265 doi (NATIONALLICENCE)springer-10.1007/BF00177265 Clinical cardiotoxicity of esorubicin (4′-deoxydoxorubicin,DxDx): Prospective studies with serial gated heart scans and reports of selected cases [Elektronische Daten] A Cancer and Leukemia Group B report [Q. Ringenberg, Kathleen Propert, Hyman Muss, Raymond Weiss, Richard Schilsky, Caron Modeas, Michael Perry, Larry Norton, Mark Green] Summary: Esorubicin (4′-deoxydoxorubicin, DxDx) has undergone extensive Phase II investigation for the treatment of cancer. Based on in vitro and animal data, esorubicin may possess less myocardial toxicity when compared to doxorubicin. One hundred thirty-six patients with histologically or cytologically documented non-small cell lung cancer or advanced breast cancer were enrolled in two concurrent CALGB clinical trials using esorubicin at a dose of 30 mg/m2 administered intravenously every 21 days. No patient had previously received an anthracycline agent or had evidence of severe cardiovascular disease. Cardiotoxicity was observed in eleven patients. Four patients developed symptoms of congestive heart failure and three asymptomatic patients had a significant fall in left ventricular ejection fraction (LVEF) as measured by gated pool heart scan. Four patients had cardiac signs or symptoms of indeterminate relationship to esorubicin therapy. Of 44 patients receiving more than four cycles of therapy, 36 patients (82%) had serial gated pool heart scans permitting assessment of subclinical myocardial toxicity. A 5% drop in LVEF was observed following approximately 240 mg/m2 esorubicin; a 10% drop was observed after approximately 480 mg/m2. If further clinical studies are undertaken with esorubicin, investigators are advised to monitor cardiac function frequently once the cumulative esorubicin dose exceeds 240 mg/m2. If congestive failure appears during therapy, prompt cessation of esorubicin and institution of inotropic agents may provide effective palliation. Normal myocardial function may be restored within several months. Kluwer Academic Publishers, 1990 esorubicin nationallicence 4′-deoxydoxorubicin nationallicence cardiotoxicity nationallicence anthracycline analog nationallicence Ringenberg Q. Harry S. Truman Memorial Veterans Hospital, Columbia, MO, USA aut Propert Kathleen Harvard School of Public Health, Boston, MA, USA aut Muss Hyman Bowman Gray School of Medicine, Wake Forest Univ. Winston-Salem, NC, USA aut Weiss Raymond Walter Reed Army Medical Center, Washington, DC, USA aut Schilsky Richard University of Chicago, Michael Reese Medical Center, Chicago, IL, USA aut Modeas Caron Frontier Science & Technology Research Foundation, Amherst, NY, USA aut Perry Michael University of Missouri-Columbia, School of Medicine, Columbia, MO, USA aut Norton Larry Mount Sinai School of Medicine, Hospital, New York, NY, USA aut Green Mark University of California-San Diego, San Diego, CA, USA aut Investigational New Drugs Kluwer Academic Publishers 8/2(1990-05-01), 221-226 0167-6997 8:2<221 1990 8 10637 https://doi.org/10.1007/BF00177265 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00177265 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Ringenberg Q. Harry S. Truman Memorial Veterans Hospital, Columbia, MO, USA aut NATIONALLICENCE 700 1- Propert Kathleen Harvard School of Public Health, Boston, MA, USA aut NATIONALLICENCE 700 1- Muss Hyman Bowman Gray School of Medicine, Wake Forest Univ. Winston-Salem, NC, USA aut NATIONALLICENCE 700 1- Weiss Raymond Walter Reed Army Medical Center, Washington, DC, USA aut NATIONALLICENCE 700 1- Schilsky Richard University of Chicago, Michael Reese Medical Center, Chicago, IL, USA aut NATIONALLICENCE 700 1- Modeas Caron Frontier Science & Technology Research Foundation, Amherst, NY, USA aut NATIONALLICENCE 700 1- Perry Michael University of Missouri-Columbia, School of Medicine, Columbia, MO, USA aut NATIONALLICENCE 700 1- Norton Larry Mount Sinai School of Medicine, Hospital, New York, NY, USA aut NATIONALLICENCE 700 1- Green Mark University of California-San Diego, San Diego, CA, USA aut NATIONALLICENCE 773 0- Investigational New Drugs Kluwer Academic Publishers 8/2(1990-05-01), 221-226 0167-6997 8:2<221 1990 8 10637 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer